Business
Why Cannabinoids Work Best Together -- CFN Media
Why Cannabinoids Work Best Together -- CFN Media.
About this update from Gb Sciences, Inc.
[{"type":"text","content":"\n \n \n Why Cannabinoids Work Best Together -- CFN Media\n \n \nWhy Cannabinoids Work Best Together -- CFN Media\n \n SEATTLE, WA--(Marketwired - Mar 7, 2017) - CFN Media Group (\"CannabisFN\"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article discussing the complex nature of the cannabis plant and the entourage effect of the plant's cannabinoids, terpenes, and other phytochemicals. GB Sciences Inc.'s (OTCQB: GBLX) holistic approach to cannabis drug development is a reflection and an embrace of this complexity.\n THC-only pharmaceuticals, like Marinol (dronabinol) and Cesamet (nabilone), have experienced limited efficacy. In fact, less than 2% of patients in a 2011 survey preferred THC-only pharmaceuticals over inhaled or infused delivery methods. CBD-only therapies have proven much more beneficial -- particularly with conditions like epilepsy -- but emerging evidence has shown that combinations of these cannabinoids could be even more beneficial.\n Dr. Than Russo, M.D., a neurologist who has become an expert in cannabinoids, notes many of these synergies in his study \"Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects,\" which details many cannabinoid interactions.\n There are also over 100 other cannabinoids in the cannabis plant that work together to reach therapeutic goals. For example, CBC is the third most common cannabinoid in the cannabis plant and works with THC to fight inflammation. THCv is another cannabinoid that has been shown to mitigate some of the negative psychoactive impacts of THC. These kinds of combinations could produce safer and more effective therapies targeting many conditions.\n GB Sciences has embraced the complexity of both the cannabis plant and endocannabinoid system. By taking a holistic approach, the company aims to leverage the natural interactions between hundreds of cannabinoids, terpenes, and other phytochemicals within the cannabis plant on many different receptors within the endocannabinoid system. These targets are identified using a high-throughput screening system that incorporates cellular and animal models of disease, as well as in silico experiments run with sophisticated algorithms.\n Recently, the company filed a series of patents covering cannabinoid-containing complex mixtures, add...